9 мар. 2023 г. · On Wednesday, after nearly 20 years of costly and unsuccessful research, Lilly conceded a final defeat for the drug, called solanezumab.

8 мар. 2024 г. · In the trial, participants could stop treatment as soon as brain imaging showed that the drug had cleared the amyloid. Lilly's White said that ...

This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional ...

8 мар. 2024 г. · Many patients in the trial discontinued the drug as early as six months; the FDA requested data on at least 100 patients who had received 12 ...

17 авг. 2010 г. · Eli Lilly halted two late-stage clinical trials of an experimental Alzheimer's treatment on Tuesday, representing a setback to one leading theory on treating ...

8 авг. 2024 г. · The company is yet again facing the harsh reality of the neurodegenerative disease with the failure of an early tau-targeting med.

8 мар. 2024 г. · Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March.

10 июн. 2024 г. · The medication doesn't cure or halt Alzheimer's disease, but it was ... In a clinical trial, three patients who received the drug died ...

3 июл. 2024 г. · The Food and Drug Administration (FDA) on Tuesday, July 2 approved the use of donanemab (Kisunla), the Alzheimer's drug that had its approval blocked last year.